Sickle Cell Disease

Introduction

Sickle cell disease (SCD) is a lifelong inherited condition that changes the shape and behaviour of red blood cells. If you or your child has been diagnosed, you may already be familiar with some of its features — episodes of pain, tiredness from anaemia, or the need for regular blood tests and clinic visits. The questions that follow a diagnosis are often practical ones: which treatments will help, how to prevent the next crisis, what to expect over the years, and whether a cure may be possible.

This guide is written for patients living with sickle cell disease and for parents caring for a child with the condition. It explains what is happening in the body, how doctors approach treatment today, and how modern therapies — from hydroxyurea to stem cell transplant and gene therapy — have changed what the future can look like. The information here is general; the right plan for any individual depends on the type of sickle cell disease, the pattern of complications, age, and a careful conversation with a haematologist.

What Is Sickle Cell Disease?

Sickle cell disease is a group of inherited disorders of haemoglobin, the protein inside red blood cells that carries oxygen from the lungs to the rest of the body. People with sickle cell disease produce an abnormal form of haemoglobin called haemoglobin S (HbS). Under certain conditions — low oxygen, dehydration, cold, infection, or stress — haemoglobin S molecules stick together inside red blood cells and pull them out of their normal round, flexible shape into a stiff crescent or “sickle” form.

These sickled cells cause two main problems:

• They block small blood vessels. Rigid sickle cells get stuck in tiny vessels, cutting off oxygen to tissues. This is what causes the sudden episodes of pain known as vaso-occlusive crises, and over years it slowly damages organs.
• They break down too quickly. Normal red blood cells live about 120 days. Sickle cells survive only 10 to 20 days. The bone marrow cannot keep up, leading to a chronic anaemia (a low number of healthy red cells) that causes fatigue and shortness of breath.

Sickle cell disease is not contagious. It is not caused by anything done or not done in pregnancy, by diet, or by lifestyle. It is a genetic condition present from conception, although symptoms usually begin in the first year or two of life when fetal haemoglobin which protects newborns is replaced by adult haemoglobin.

Types of Sickle Cell Disease

Sickle cell disease is not one disease but a family of related disorders. The type depends on which combination of haemoglobin genes a person has inherited from each parent. Knowing the type matters because it influences how severe symptoms are likely to be and how doctors plan care.

Sickle cell anaemia (HbSS)

This is the most common and usually the most severe form. The person has inherited the sickle haemoglobin gene from both parents. Anaemia tends to be more pronounced and pain crises more frequent.

Haemoglobin SC disease (HbSC)

The person inherits one sickle gene and one gene for haemoglobin C, another abnormal haemoglobin. Anaemia is often milder, but complications such as eye problems (retinopathy), avascular necrosis of the hip, and acute chest syndrome still occur.

Sickle beta-thalassaemia (HbS-beta-thal)

The person inherits one sickle gene and one beta-thalassaemia gene. Severity depends on whether the thalassaemia gene produces no normal haemoglobin (HbS-beta-zero, behaves much like HbSS) or some normal haemoglobin (HbS-beta-plus, often milder).

Sickle cell trait (HbAS)

A person with sickle cell trait has inherited the sickle gene from only one parent and a normal gene from the other. Sickle cell trait is not sickle cell disease. People with the trait usually have no symptoms and live normal lives, although in rare situations — intense exercise at altitude, severe dehydration, or certain anaesthetic conditions — problems can occur. Sickle cell trait is important because two people with the trait can pass the disease to their children.

Causes and Risk Factors

Sickle cell disease is caused by a single change (mutation) in the gene that codes for the beta-globin part of haemoglobin. This change replaces one amino acid with another and gives haemoglobin its sickling property under low-oxygen conditions.

The gene is inherited in an autosomal recessive pattern. This means:

• If both parents carry one sickle gene (have sickle cell trait), each child has a 1 in 4 chance of having sickle cell disease, a 1 in 2 chance of having sickle cell trait, and a 1 in 4 chance of inheriting neither.
• If one parent has sickle cell disease and the other has the trait, each child has a 1 in 2 chance of having the disease and a 1 in 2 chance of having the trait.

The condition is most common in people whose ancestors come from sub-Saharan Africa, parts of India (particularly central and tribal regions), the Middle East, the Mediterranean, and the Caribbean. In India, sickle cell disease is concentrated in certain tribal and rural populations, and the Government of India has launched a national programme aimed at screening and reducing the burden of the condition.

Triggers that can bring on a pain crisis or other complication include dehydration, infection, fever, cold weather, sudden temperature changes, low oxygen at high altitudes, strenuous physical exertion, emotional stress, alcohol, and smoking. Knowing personal triggers is part of self-management.

Signs and Symptoms

If you or your child already has a diagnosis, you will be familiar with many of these features. They are listed here because recognising the pattern of complications — and knowing which symptoms need urgent attention — is central to ongoing care.

Chronic anaemia

Persistent tiredness, breathlessness on exertion, pale or yellowish skin, and a faster heartbeat reflect the steady low haemoglobin most people with sickle cell disease carry day to day.

Vaso-occlusive crisis (pain crisis)

The hallmark of sickle cell disease. Pain can begin suddenly, lasting hours to days, and is often felt in the back, chest, abdomen, arms, legs, or joints. Some crises can be managed at home with fluids, warmth, and oral pain medication. Others need hospital treatment with intravenous fluids and stronger pain relief.

Dactylitis

Painful swelling of the hands and feet, often the first symptom in young children.

Acute chest syndrome

A serious lung complication causing chest pain, fever, cough, and breathlessness. It can develop quickly and requires urgent hospital care.

Infections

The spleen, which helps fight certain bacteria, is often damaged early in sickle cell disease. This raises the risk of severe infections, particularly from organisms such as pneumococcus.

Stroke and silent brain injury

Sickle cell disease increases the risk of stroke, especially in childhood. “Silent” strokes — small areas of brain injury without obvious symptoms — can also affect learning and concentration.

Other complications over time

• Jaundice and gallstones from the rapid breakdown of red cells
• Kidney problems and blood in the urine
• Eye changes (sickle retinopathy), particularly in HbSC disease
• Bone damage, including avascular necrosis of the hip or shoulder
• Leg ulcers
• Priapism (prolonged, painful erections) in males
• Pulmonary hypertension (raised pressure in lung arteries)
• Delayed growth and puberty in some children

Severity varies enormously. Two people with the same type of sickle cell disease may have very different lives — one may have many crises a year, another almost none.

Diagnosis

For most people reading this article, the diagnosis has already been made. The tests below are described so you can understand what was done, what tests may be repeated, and how new family members (such as future children) are tested.

Newborn screening

Many countries, including parts of India under the National Sickle Cell Anaemia Elimination Mission, test newborns with a simple heel-prick blood sample. Early identification allows penicillin prophylaxis and other preventive care to begin in the first few months of life.

Haemoglobin electrophoresis or HPLC

These laboratory techniques separate the different types of haemoglobin in the blood and identify haemoglobin S, C, and others. They confirm both the diagnosis and the specific type of sickle cell disease.

Complete blood count and blood film

Shows the degree of anaemia and may reveal sickle-shaped cells under the microscope.

Genetic (DNA) testing

Used in selected situations — for example, to clarify ambiguous results, to test family members, or for prenatal diagnosis when both parents carry the sickle gene.

Carrier and prenatal testing

Couples planning a family who know they may be carriers can be tested before pregnancy. During pregnancy, testing of the developing baby (through chorionic villus sampling or amniocentesis) can identify whether the child will have sickle cell disease. Counselling helps families understand the implications of any result.

Treatment and Management

Sickle cell disease is managed across several layers: preventing complications before they happen, modifying the underlying disease with medication, treating crises and complications when they occur, and, for some patients, pursuing a curative therapy. Decisions about which combination is right depend on the type of sickle cell disease, the pattern of complications, age, and personal circumstances.

Preventive care

Preventive measures are the foundation of sickle cell disease care from the earliest months of life.

• Penicillin prophylaxis. Daily oral penicillin from infancy through at least age five (sometimes longer) substantially reduces the risk of life-threatening pneumococcal infection.
• Vaccinations. A full schedule including pneumococcal, meningococcal, Haemophilus influenzae type b, influenza, hepatitis B, and other recommended vaccines is essential.
• Folic acid. A daily supplement supports red cell production.
• Transcranial Doppler (TCD) ultrasound screening. In children with HbSS or HbS-beta-zero thalassaemia, this painless scan checks blood flow in brain arteries and identifies children at high stroke risk who may benefit from a transfusion programme.
• Regular review with a haematologist to monitor blood counts, organ function, eyes, kidneys, lungs, and growth.

Hydroxyurea

Hydroxyurea (also called hydroxycarbamide) is the most established disease-modifying medication for sickle cell disease and has been used for decades. It works largely by increasing the amount of fetal haemoglobin (HbF) the body produces. Fetal haemoglobin interferes with the sickling process, so red cells stay flexible for longer.

Studies have shown that hydroxyurea can reduce the frequency of pain crises, episodes of acute chest syndrome, hospital admissions, and the need for transfusions. Current guidelines from the American Society of Hematology (ASH) and the NHLBI describe hydroxyurea as a foundational therapy that should be offered to children and adults with HbSS and HbS-beta-zero thalassaemia, and considered in other types of sickle cell disease based on individual circumstances.

Hydroxyurea is taken by mouth, usually once a day. Blood counts are monitored regularly, particularly when starting or adjusting the dose, because the medication can lower white cell and platelet counts. Common side effects are usually mild. Whether and when to start hydroxyurea is a clinical decision made with a haematologist.

Newer disease-modifying medications

Several newer medications have been approved in recent years for sickle cell disease, each working in a different way. Availability varies by country.

• L-glutamine — an oral amino acid supplement that may reduce the frequency of pain crises in some patients.
• Crizanlizumab — a monoclonal antibody given by intravenous infusion that targets a molecule (P-selectin) involved in blood cells sticking to vessel walls. In studies it reduced the frequency of pain crises.
• Voxelotor — an oral medication that helps haemoglobin hold on to oxygen, reducing sickling and raising haemoglobin levels. (Patients should be aware that voxelotor was withdrawn from some markets in 2024 following post-marketing safety review; whether it is available depends on current regulatory status in the country of treatment.)

These medications can be used alongside hydroxyurea in some patients. Suitability depends on age, type of sickle cell disease, pattern of complications, and what is locally available.

Pain crisis management

Crisis management has two parts: what you can do at home and when to go to hospital.

At home, mild to moderate pain is often managed with rest, warmth (heating pads, warm baths), generous fluid intake, and oral pain medication such as paracetamol or anti-inflammatory drugs if approved by your doctor. Many adults with frequent crises have a personalised home plan that may include stronger pain medication.

Hospital care becomes necessary when pain is severe, not responding to home measures, or when warning features appear: high fever, chest pain or shortness of breath, severe headache or weakness, persistent vomiting, signs of dehydration, or any new neurological symptom. Hospital treatment usually involves intravenous fluids, opioid pain relief, oxygen if needed, and treatment of any infection or other trigger.

Reliable pain control is a right, not a privilege. Guidelines from major haematology societies stress that people with sickle cell disease should not face delays or under-treatment of crisis pain. Keeping a written pain plan from your haematologist to show in emergency departments can help.

Blood transfusions

Transfusion of healthy donor red blood cells reduces the proportion of sickled cells in circulation and improves oxygen delivery. Transfusions are used in several situations:

• Acute transfusion — for severe anaemia, acute chest syndrome, stroke, splenic sequestration, or before major surgery.
• Chronic (regular) transfusion programmes — usually every three to four weeks, most often for children at high stroke risk on TCD screening or those who have already had a stroke. They may also be used in some adults with frequent severe complications.
• Exchange transfusion — sickled cells are removed and replaced with donor cells in one procedure, used in serious complications and in some chronic programmes.

Long-term transfusion can cause a build-up of iron in the body (iron overload), which damages the heart, liver, and other organs. Iron is monitored with blood tests and MRI scans, and iron-removing medications (chelation therapy) are used to keep levels safe.

Stem cell (bone marrow) transplant

Allogeneic haematopoietic stem cell transplant — receiving stem cells from a matched donor — is currently the most established curative treatment for sickle cell disease. The donor’s healthy bone marrow replaces the patient’s, so the body begins to make normal red blood cells.

Transplant is generally considered when the disease is severe (frequent crises, stroke or high stroke risk, recurrent acute chest syndrome, or other serious complications), when a suitable donor is available (usually a brother or sister who is an HLA match), and when the patient is medically fit. Outcomes are best in children with a matched sibling donor, and most patients in this group are cured of sickle cell disease. Transplants from less closely matched donors are also being performed at experienced centres.

The process involves an evaluation of organ function and overall health, conditioning chemotherapy (and sometimes radiotherapy) to make space for the donor cells, the infusion of stem cells, several weeks in hospital while the new marrow engrafts, and many months of careful follow-up. Risks include infection, graft-versus-host disease (where donor immune cells attack the recipient’s tissues), infertility, and, less commonly, graft failure or death. These risks have to be weighed against the burden of life with severe sickle cell disease. The decision to pursue transplant is made carefully with a specialist transplant team.

Gene therapy

Gene therapy is the newest curative approach for sickle cell disease. Two gene therapies were approved by the United States FDA in late 2023 — one based on CRISPR gene editing and one using a gene addition approach. Both work by collecting the patient’s own stem cells, modifying them in a laboratory so that the body produces either fetal haemoglobin or a non-sickling form of adult haemoglobin, and then returning the modified cells after conditioning chemotherapy.

Early results have been very encouraging, with most patients in clinical trials becoming free of pain crises. Because the patient’s own cells are used, there is no risk of graft-versus-host disease and no need for an HLA-matched donor. The procedure still requires conditioning chemotherapy, with its associated risks including infertility, and long-term outcomes over many years are still being studied. Access varies considerably by country, with availability in India currently limited to selected centres and clinical trial settings.

Whether stem cell transplant or gene therapy — or neither — is the right path is a clinical conversation that depends on disease severity, age, donor availability, organ status, and personal values.

Lifestyle and Self-Management

Daily choices have a meaningful effect on how often crises occur and how well organs are protected over time.

Hydration

Drinking plenty of water throughout the day is one of the simplest and most effective ways to reduce sickling. Increase intake further in hot weather, during exercise, when unwell, or during travel.

Temperature

Sudden cold and large temperature changes are common triggers. Dress warmly in cold weather, avoid swimming in cold water, and protect against air-conditioning blasts.

Activity

Moderate, regular physical activity is encouraged and supports general health. Extreme exertion to the point of exhaustion, particularly without enough fluids, can trigger a crisis. People with sickle cell disease should be cautious about high-altitude travel, unpressurised flights, and intense exercise at altitude.

Infection prevention

Keep vaccinations up to date, including annual influenza vaccination. Seek prompt medical attention for any fever, especially in children, where fever can be the first sign of serious infection.

Smoking and alcohol

Smoking damages the lungs and worsens sickle cell complications; it should be avoided. Alcohol contributes to dehydration and should be limited.

Diet

A balanced diet supports overall health. Folic acid is usually prescribed. Iron supplements should not be taken unless specifically prescribed, because iron overload is already a concern in transfused patients.

Sleep and stress

Poor sleep and high stress can precede crises. Pacing daily life, building in rest, and finding stress-management strategies that work for you — whether that is exercise, meditation, faith practices, or talking with others — can help.

Travel

Plan ahead. Discuss long flights and high-altitude destinations with your haematologist. Carry a summary of your diagnosis, medications, and a contact for your treating doctor. Insurance and medical access at the destination matter.

Monitoring and Follow-Up

• Blood counts and kidney/liver function at least once or twice a year (more often if on hydroxyurea, transfusions, or other treatments)
• Annual eye examination to look for sickle retinopathy
• Annual urine test for kidney involvement
• Echocardiogram periodically to screen for pulmonary hypertension
• Transcranial Doppler screening in children with HbSS or HbS-beta-zero thalassaemia from about age 2 until 16
• Iron monitoring (ferritin, liver MRI) for those on chronic transfusion
• Bone and hip evaluation if symptoms suggest avascular necrosis
• Mental health and psychosocial review — chronic illness, pain, and uncertainty take a toll, and support is part of complete care

Complications and When to Seek Urgent Care

Some symptoms always need same-day medical attention. Keep this list accessible at home, especially for children:

• Fever above 38.5°C (101.3°F), or any fever in a young child
• Severe pain not controlled by usual home measures
• Chest pain, difficulty breathing, or low oxygen levels
• Sudden weakness, numbness, slurred speech, severe headache, vision changes, or any other sign suggesting stroke
• Severe abdominal pain or a rapidly enlarging spleen (parents may be taught to feel for this in young children)
• Priapism lasting more than four hours
• Severe paleness or unusual tiredness, suggesting a sudden drop in haemoglobin
• Persistent vomiting or signs of dehydration

Going to hospital early is far safer than waiting. Many serious sickle cell complications respond well to prompt treatment.

Living with Sickle Cell Disease

Sickle cell disease shapes daily life, but it does not define it. With modern care, many people with sickle cell disease complete their education, build careers, have families, and enjoy long, full lives. There are real challenges to navigate.

Emotional and mental health

Living with chronic pain, hospital visits, and uncertainty can lead to anxiety, low mood, and burnout. Depression is more common in people with sickle cell disease than in the general population. Talking with a counsellor or psychologist, peer support groups, and good communication within the family all help.

Education and work

Children with sickle cell disease may miss school during crises or have learning difficulties from silent strokes. Schools can be told about the condition so that adjustments — freedom to drink water, access to the toilet, extra time after absences, warmth indoors — can be arranged. Adults often benefit from a frank conversation with their employer about needs, particularly around hydration, temperature, and recovery time after crises.

Family planning and pregnancy

Many women with sickle cell disease have successful pregnancies, but pregnancy is higher risk and requires care from both an obstetrician and a haematologist. Some medications used for sickle cell disease, including hydroxyurea, are usually stopped before pregnancy. Testing the partner’s haemoglobin status helps couples understand the chance of having a child with sickle cell disease.

Pain that is not believed

People with sickle cell disease sometimes describe being doubted in emergency departments, especially when they have no visible signs of illness but need opioid pain relief. A written individualised pain plan from your haematologist, and ideally a sickle cell specialist or hospital you can return to, makes a real difference.

Sickle Cell Disease in Children

Children with sickle cell disease have specific needs that differ from adult care.

Early life

Penicillin prophylaxis

Daily penicillin from a few months of age through to at least five years (sometimes longer) is a cornerstone of paediatric sickle cell care because of the high risk of pneumococcal infection in young children with damaged spleens.

Stroke prevention

Children with HbSS or HbS-beta-zero thalassaemia have a measurable stroke risk in childhood. Transcranial Doppler ultrasound, performed regularly from about age 2 to 16, identifies children with high-risk blood flow who benefit from a chronic transfusion programme.

Hydroxyurea in children

Hydroxyurea is now recommended by major guidelines from as early as 9 months of age in children with HbSS or HbS-beta-zero thalassaemia, regardless of severity, because of its long-term protective effects. The decision and dose are managed by a paediatric haematologist.

Growth, puberty, and school

Some children grow more slowly and enter puberty later. Most catch up. School absences, fatigue, and silent strokes can affect learning, so educational support and regular cognitive monitoring may be helpful.

Transplant in childhood

For children with a matched sibling donor, stem cell transplant in childhood — before complications accumulate — offers the highest chance of cure with the lowest risk. Families considering this option are usually referred to a paediatric transplant centre for full discussion.

The transition to adult care

Moving from paediatric to adult haematology services in the late teens is a vulnerable time. A planned transition, with overlap between teams and the young person taking gradual ownership of their care, helps prevent gaps.

Preventing Progression and Complications

While sickle cell disease itself cannot be prevented without changing the genes, much can be done to slow its progression and reduce damage:

• Take disease-modifying medication consistently if prescribed
• Attend all monitoring appointments, including eye, kidney, and heart checks
• Keep vaccinations current
• Recognise personal crisis triggers and avoid them where possible
• Treat infections early
• Maintain hydration, warmth, and rest
• Do not smoke; limit alcohol
• Talk openly with your haematologist about new therapies as they become available

Frequently Asked Questions

Is sickle cell disease curable?

Yes, for some patients. Allogeneic stem cell transplant from a matched donor is the most established curative therapy and offers a high chance of cure, particularly in children with a matched sibling donor. Gene therapy is a newer curative option approved in some countries. Both involve significant treatment and risks and are not suitable for everyone.

Can sickle cell disease be managed well without transplant?

Many people manage sickle cell disease for life with hydroxyurea, preventive care, transfusions when needed, and prompt treatment of complications. Outcomes have improved significantly in recent decades.

Will hydroxyurea cause cancer?

This concern has been studied carefully over many years. The evidence does not show an increased risk of cancer in people with sickle cell disease taking hydroxyurea. Major guidelines from haematology societies describe hydroxyurea as safe for long-term use under monitoring.

Can people with sickle cell disease have children?

Yes. Both men and women with sickle cell disease can have children, although fertility may be affected by some treatments (including stem cell transplant and gene therapy conditioning, and hydroxyurea in some cases). Family planning conversations, including testing the partner’s haemoglobin status, are an important part of care. Pregnancy in women with sickle cell disease is higher risk and benefits from joint obstetric and haematology care.

Is the pain “all in the head” or exaggerated?

No. Pain in sickle cell disease is caused by real tissue injury when sickled cells block blood vessels. Patients sometimes face scepticism in healthcare settings because the pain is invisible. A written individualised pain plan from your haematologist can support consistent treatment.

Does sickle cell trait need treatment?

Sickle cell trait is not a disease and does not need treatment. Most people with the trait live without symptoms. The main importance of identifying the trait is for family planning, because two people with the trait can have a child with sickle cell disease.

How often will I need to see a haematologist?

This depends on the type of sickle cell disease, treatments, and any complications. Many adults are seen at least once or twice a year when stable, and more often during pregnancy, when starting new medications, or after complications. Children are usually seen more frequently.

Can sickle cell disease affect life expectancy?

Life expectancy has improved substantially over the past few decades thanks to newborn screening, infection prevention, hydroxyurea, transfusion programmes, and better complication management. Many people now live into their fifties, sixties, and beyond. The picture continues to improve as newer therapies become more widely available.

Should I look for a particular kind of doctor or centre?

Care is best coordinated by a haematologist with experience in sickle cell disease. For more complex care — chronic transfusion, transplant, gene therapy — a comprehensive sickle cell centre or a bone marrow transplant unit with sickle cell experience is generally where treatment happens. Building a long-term relationship with one team helps maintain continuity over years.

Conclusion

Sickle cell disease is a lifelong condition, but the outlook today is very different from what it was a generation ago. With newborn screening, infection prevention, hydroxyurea and newer disease-modifying medications, well-run transfusion programmes, and curative options including stem cell transplant and gene therapy, most people with sickle cell disease can expect a longer and more stable life than was once possible.

Living well with sickle cell disease is a partnership: between you and your haematology team, between specialists in different areas of care, and within your own family. Understanding the condition, recognising warning signs, sticking with preventive care, and staying connected to a knowledgeable centre are the steady habits that protect the future. The therapies on the horizon — refined gene editing, simpler transplant approaches, better pain management — suggest that the next decade will continue to expand what is possible for people living with sickle cell disease.